Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
The MIT researchers said that the mutational signature could be used to identify people exposed to aflatoxin who are at risk of developing liver cancer.
The Broad Institute's lawyers used statements from Jennifer Doudna to undermine UC's case that one could expect CRISPR/Cas9 to work in eukaryotic cells.
